# Denosumab for Treating Periprosthetic Osteolysis.

> **NCT02299817** · PHASE2 · UNKNOWN · sponsor: **Olof Skoldenberg** · enrollment: 20 (actual)

## Conditions studied

- Osteolysis

## Interventions

- **DRUG:** Denosumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02299817
- **Lead sponsor:** Olof Skoldenberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2021-01
- **Final completion:** 2021-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02299817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02299817, "Denosumab for Treating Periprosthetic Osteolysis.". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02299817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*